A mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis

Lead Research Organisation: Imperial College London
Department Name: Immunology and Inflammation


There is a need for new therapies to reduce time to remission in patients suffering from ANCA associated Vasculitis treated with Rituximab. This projects mechanistically investigates the utility of targeting the Bcell survival factor B-Lys in combination with rituximab in reducing remission in the setting f ANCA associated Vasculitis

Technical Summary

Experimental medicine study to investigate the combination of belimumab and rituximab in man


10 25 50